TY  - GEN
AU  - Rodriguez-Nunez, Olga
AU  - Periáñez Párraga, Leonor
AU  - Oliver, Antonio
AU  - Munita, Jose M
AU  - Bote, Anna
AU  - Gasch, Oriol
AU  - Nuvials, Xavier
AU  - Dinh, Aurelien
AU  - Shaw, Robert
AU  - Lomas, Jose M
AU  - Torres, Vicente
AU  - Caston, Juanjo
AU  - Araos, Rafael
AU  - Abbo, Lilian M
AU  - Rakita, Robert
AU  - Perez, Federico
AU  - Aitken, Samuel L
AU  - Arias, Cesar A
AU  - Luisa Martin-Pena, M
AU  - Colomar Ferra, Maria Asuncion
AU  - Belen Nunez, M
AU  - Mensa, Josep
AU  - Antonio Martinez, Jose
AU  - Soriano, Alex
PY  - 2019
DO  - 10.1093/ofid/ofz416
SN  - 2328-8957
UR  - https://hdl.handle.net/20.500.12105/22787
AB  - Background. Ceftolozane/tazobactam (C/T) efficacy and safety in ventilator-associated pneumonia (VAP) is being evaluated at a double dose by several trials. This dosing is based on a pharmacokinetic (PK) model that demonstrated that 3 g q8h achieved...
LA  - eng
PB  - Oxford University Press
KW  - Ceftolozane/tazobactam
KW  - Multidrug-resistant
KW  - Pneumonia
KW  - Pseudomonas aeruginosa
KW  - Tracheobronchitis
TI  - Higher MICs (> 2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa Treated With Ceftolozane/Tazobactam
TY  - research article
ER  -